Switching to omnichannel in pharma: What are the challenges?

08/17/2022 By Andrea

Article authored and contributed to PharmaLeaders by: Pavel Klymenko, Head of Omnichannel Hub at Viseven I’ve been in digital marketing for more than 15 years. From the beginning of my career, I witnessed the evolution of online communication in different markets. With the increasing number of messages sent by many companies via multiple platforms, customers got […]

Validcare announces the integration of Real-World Research (RWR) Ltd into the Validcare Digital 1st CRO platform

08/04/2022 By Andrea

Denver, CO. – August 2, 2022 Today, Validcare announces the integration of Real-World Research (RWR) Ltd into the Validcare Digital 1st CRO platform. RWR is a global leader in providing Real-World Evidence solutions to the pharmaceutical, biotech and medical device industries. Dr. Stuart McCully, CEO of RWR said “Until now we’ve provided sponsors with the regulatory intelligence […]

AeroRx, HCmed to develop nebulised combination formulation for COPD

10/03/2022

The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution The post AeroRx, HCmed to develop nebulised combination formulation for COPD appeared first on … [Read More...]

FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine

10/01/2022

The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen The post FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine appeared first on … [Read More...]

Vanda partners with OliPass to develop ASO-based therapeutics

09/30/2022

The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It The post Vanda partners with OliPass to develop ASO-based therapeutics appeared first on … [Read More...]

US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis

09/29/2022

This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human The post US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis appeared first on Pharmaceutical Business … [Read More...]

Featured Article

Switching to omnichannel in pharma: What are the challenges?

Validcare announces the integration of Real-World Research (RWR) Ltd into the Validcare Digital 1st CRO platform

White Papers

Whitepaper: Execute a 5-Step Framework for Data Compliance in Healthcare Marketing in the 2020s

Engaging Users of Healthcare Provider Communities

Industry News

AeroRx, HCmed to develop nebulised combination formulation for COPD

FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine

Vanda partners with OliPass to develop ASO-based therapeutics

US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis